Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer

Supplementary Fig. S1 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer

<p>Supplementary Fig. S1. The structure of mTOR complexes and overview of the PI3K/AKT/mTOR signaling pathway. The mTOR signaling pathway is implicated in a variety of major cellular processes, from cell growth to apoptosis. mTOR nucleates at least two distinct multi-protein complexes, mTORC1...

Повний опис

Збережено в:

Бібліографічні деталі
Автор:	Sahar Mafi (16721657) (author)
Інші автори:	Elham Ahmadi (16721660) (author), Eileen Meehan (16721663) (author), Conner Chiari (16721666) (author), Behzad Mansoori (16721669) (author), Hossein Sadeghi (16721672) (author), Sahar Milani (16721675) (author), Morteza Jafarinia (16721678) (author), Shahram Taeb (16721681) (author), Bayan Mafakheri Bashmagh (16721684) (author), Seyed Mohammad Ali Mansoorian (16721687) (author), Mohammad Sadegh Soltani-Zangbar (16721690) (author), Kepeng Wang (16721693) (author), Davoud Rostamzadeh (16721696) (author)
Опубліковано:	2025
Предмети:	Cancer Immuno-oncology Immunotherapy Biomarkers for immunotherapy Cellular immunotherapy
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси

Supplementary Fig. S2 from The mTOR Signaling Pathway Interacts with the ER Stress Response and the Unfolded Protein Response in Cancer
за авторством: Sahar Mafi (16721657)
Опубліковано: (2025)

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
за авторством: Jian Wang (15048011)
Опубліковано: (2025)

Supplementary File 1 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
за авторством: Huaibin Ge (15047462)
Опубліковано: (2025)

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Figure S9 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Table S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
за авторством: Rohit Thummalapalli (17314483)
Опубліковано: (2025)

Video 2_Doxorubicin induces cardiotoxicity by enhancing autophagy via mTOR signaling in hiPSC- and hESC-derived cardiomyocytes.mp4
за авторством: Minxia Ke (4889887)
Опубліковано: (2025)

Data Sheet 1_Doxorubicin induces cardiotoxicity by enhancing autophagy via mTOR signaling in hiPSC- and hESC-derived cardiomyocytes.docx
за авторством: Minxia Ke (4889887)
Опубліковано: (2025)

Video 1_Doxorubicin induces cardiotoxicity by enhancing autophagy via mTOR signaling in hiPSC- and hESC-derived cardiomyocytes.mp4
за авторством: Minxia Ke (4889887)
Опубліковано: (2025)

Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
за авторством: Julio C. Chavez (15181310)
Опубліковано: (2025)

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
за авторством: Julio C. Chavez (15181310)
Опубліковано: (2025)

Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
за авторством: Julio C. Chavez (15181310)
Опубліковано: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
за авторством: Stéphane Fattori (15048281)
Опубліковано: (2025)

Cannot write session to /tmp/vufind_sessions/sess_cvbjrkpsoese05e1glf1tl7o71